Clinical Trials Logo

Mouth Diseases clinical trials

View clinical trials related to Mouth Diseases.

Filter by:

NCT ID: NCT03438045 Recruiting - Dental Caries Clinical Trials

Implementing a Participatory, Multi-level Intervention to Improve Asian American Health Study

Start date: May 9, 2018
Phase: N/A
Study type: Interventional

This feasibility and acceptability study will be conducted at 3 community outreach centers serving an urban, low-income Chinese population. The study will evaluate the feasibility and acceptability of implementing a partnered intervention to improve the oral and general health of low-income, urban Chinese American adults and of using remote data entry into an electronic health record (EHR). The research staff will survey a sample of Chinese American patients screened at each center about their satisfaction with the partnered intervention and about their oral health behaviors. An additional sample selected from providers [dentists and community health workers (CHW)], research staff, New York University (NYU) administrators, site directors, and community advisory board (CAB) members will participate in structured interviews about the partnered intervention. The remote EHR evaluation will include group adaptation sessions and workflow analyses via multiple recorded sessions with research staff, NYU administrators, outreach site directors, and providers (dentists and CHWs). The study will also model knowledge held by these non-patient participants (including CAB members) to evaluate and enhance the partnered intervention during and/or after the feasibility and acceptability study for use in future implementations.

NCT ID: NCT03429829 Recruiting - Dental Caries Clinical Trials

Caries Prophylaxis With Flairesse Fluoride Varnish

Start date: February 12, 2018
Phase: N/A
Study type: Interventional

Clinical study to evaluate the efficiency of Flairesse fluoride varnish in improving dental health in South African school children.

NCT ID: NCT03365570 Not yet recruiting - Clinical trials for Oral Disease , Iron Deficiency Anemia

Prevalence of Oral Manifestations of Iron Deficiency Anemia in Egyptian Population

Start date: December 2017
Phase: N/A
Study type: Observational

According to WHO Report (2002), iron deficiency anemia was considered to be the most important contributing factor to the global burden of anemia. Children and women in reproductive ages are more at risk factor for developing iron deficiency anemia (Suneeta, 2007).No previous study has been held to assess prevalence of oral manifestations of iron deficiency anemia as a hospital-based cross-sectional study on a sample of Egyptian patients in hematology department (no previous data recorded).

NCT ID: NCT03296410 Enrolling by invitation - Clinical trials for Hand, Foot and Mouth Disease (HFMD)

The Phase IVd of Inactivated Enterovirus 71 Vaccine

Start date: September 14, 2017
Phase: Phase 4
Study type: Interventional

Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Its infection occasionally leads to severe diseases and death, with central nervous system (CNS) damage. Recently, except of inactivated vaccine, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been finished phase I, II and III clinical trials and licensed by SFDA in China at Dec. 3, 2015. Based on the results of clinical trials, the protective efficacy of inactivated EV71 vaccine is 97% against HFMD caused by EV71. The phase IV clinical trial has been carried out from July 2016. The purpose of phase IVd is to evaluated the immunogenicity and safety of the inactive EV71 vaccine within two measles attenuated live vaccine and live attenuated Japanese encephalitis vaccine at the same time point in large scale population of Chinese children (8 months old) in Guangdong Province, China.

NCT ID: NCT03281174 Completed - Clinical trials for Hand, Foot and Mouth Disease

Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine

Start date: May 20, 2017
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the 5-year Immune Persistence of Inactivated Enterovirus Type 71 (EV71) Vaccine manufactured by Sinovac (Beijing) Biotech Co., Ltd.

NCT ID: NCT03278132 Recruiting - Clinical trials for Hand, Foot and Mouth Disease

Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

Start date: July 16, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different time after vaccination

NCT ID: NCT03274102 Recruiting - Clinical trials for Hand, Foot and Mouth Disease

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Start date: April 22, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine.

NCT ID: NCT03241030 Enrolling by invitation - Clinical trials for Hand, Foot and Mouth Disease

Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial

Start date: September 12, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if sucralfate, a medication commonly used for patients with stomach ulcers, may help pediatric patients with mouth ulcers decrease their pain level and improve their ability to drink.

NCT ID: NCT03240744 Active, not recruiting - Clinical trials for Hand, Foot and Mouth Disease (HFMD)

The Phase IVc of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell)

Start date: June 22, 2017
Phase: Phase 4
Study type: Interventional

Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Its infection occasionally leads to severe diseases and death, with central nervous system (CNS) damage. Recently, except of inactivated vaccine, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been finished phase I, II and III clinical trials and licensed by SFDA in China at Dec. 3, 2015. Based on the results of clinical trials, the protective efficacy of inactivated EV71 vaccine is 97% against HFMD caused by EV71. The phase IV clinical trial has been carried out from July 2016. The purpose of phase IVc is to evaluated the immunogenicity of the inactive EV71 vaccine in large scale population of Chinese children (from 6 to 71 months old) in Hubei Province, China.

NCT ID: NCT03123705 Recruiting - Oral Disease Clinical Trials

El Paso Public Health Biorepository

EPB
Start date: May 26, 2017
Phase: N/A
Study type: Observational

The prevalence of tooth decay and other oral disease are often overlooked indicators of overall public health. To improve the understanding of oral health in El Paso, the City of El Paso Health Department has teamed up with Texas Tech University Health Sciences Center El Paso in a collaborative effort to determine the factors that contribute to poor oral hygiene, and lead to cavities and periodontitis. The team will collect saliva, oral debris, leftover teeth and plaque from children and young adults to study oral infections, markers of inflammation, and other contributors to tooth decay and oral illnesses. Samples also will be stored for future investigations. This joint effort will provide a better picture of oral health in El Paso, and will define a framework for prevention, earlier diagnosis, and better treatment.